The development of HCC is promoted by FGF21 amplification via the TGF-β signaling pathway and patients having higher baseline FGF21 appeared to have better OS with lenvatinib than sorafenib (42).Cell survival, growth, proliferation, and differentiation was also limited by lenvatinib via blocking the RET receptor, which is associated with numerous signaling pathways, including PI3K/AKT and RAS/MAPK pathways (42, 63). Here, FGF21 is linked to hepatocellular carcinoma.